Challenger Rejects $5.5 Billion Offer for Remaining Stake at 17.7% Premium
Key Facts
Challenger’s board rejected an indicative, non-binding offer from Japanese group Dai-ichi Life’s Australian unit TAL to acquire the shares it does not own, in an update published on October 26. The proposal, which Challenger said it received on October 19, set a price of A$11.80 a share to buy the remaining 79.5% stake and raise TAL’s ownership to 100%. The purchase of that stake is valued at about US$4.4 billion, while the offer values all of Challenger at A$7.94 billion, or about US$5.5 billion. According to coverage by Investing.com citing Reuters, the valuation represents the total value of the company, not the purchase price of the remaining stake alone. Dai-ichi Life confirmed the proposal was non-binding and that it had not yet decided whether to proceed with a binding transaction.
The proposed price was above the share’s pre-announcement trading levels, including a 17.7% premium to the one-month volume-weighted average price of A$10.03. It also represented a 19.8% premium to the previous close of A$9.85. The board nevertheless rejected the offer in its current form, leaving the door open to further discussions. That position does not guarantee an improved offer or that talks will lead to a binding agreement. The proposal’s existing terms, including its price and the targeted shareholding, remain the basis of the offer received by the company in October.
The initial announcement of the offer quickly affected Challenger shares, which rose 16.65% to A$11.49 in the session when it was announced, reaching their highest level since October 22, 2018. The S&P/ASX 200 was little changed in the same session, according to data cited by Investing.com. The market reaction after the board’s rejection was more subdued; Bloomberg coverage cited by The Japan Times said shares in Challenger and Dai-ichi Life saw little change on Monday. This places the sharp share move when the price was announced in a different context from trading after its rejection. Those moves alone do not determine the outcome of the negotiations.
Dai-ichi Life owned 20.36% of Challenger at the time of the offer, after buying an initial minority stake of 15.1% from MS&AD Insurance Group in April 2025. Buying the remaining shares would have turned that holding into full ownership of the company, if the deal were completed. Challenger’s latest operating results provide additional context for assessing the proposal: in the first quarter of fiscal 2027, funds under management rose 5% from the previous quarter to A$31.9 billion. Gross sales increased 52% year over year to A$4.4 billion in the same quarter. These figures show business growth over two different comparison periods, without determining on their own why the board rejected the price.
As for next steps, Dai-ichi Life said no decision had been made on proceeding with a binding transaction and that it would make an announcement in due course if circumstances requiring disclosure arose. The proposal therefore remains non-binding, and the group’s statement does not confirm that the deal will proceed. Australian inflation data showed the Consumer Price Index rose 4.3% in the 12 months to September 2026, compared with 4.0% to August, and increased 0.8% in September. The Australian Bureau of Statistics set November 25, 2026, as the release date for October’s index data. These figures form part of the Australian economic backdrop, with no stated connection to Challenger’s decision to reject the offer.